Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application

Abstract

A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

1 - 131 . (canceled) 
     
     
         132 . A composition for treating kerato-conjunctivitis sicca (dry eye syndrome) comprising:
 i. between about 0.005% and 5% weight-by-weight of estrogen or an estrogen analog or other estrogen receptor modulator; and   ii. a thermosetting poloxamer or polyethylene glycol gel which is a clear physiologically acceptable solution at room temperature or lower but which forms a gel when placed in the eye,   wherein the composition has a sustained drug release rate which delivers a dose of between 0.1 mg/ml and 1.0 mg/ml of estrogen or estrogen analog per hour for at least about 6-8 hours after application, as measured by a Franz diffusion cell model with simulated tear flow.   
     
     
         133 . The composition according to  claim 132 , wherein the estrogen or estrogen analog or other estrogen receptor modulator is at a concentration of between about 0.005% and less than 0.05% weight-by-weight in the composition. 
     
     
         134 . The composition according to  claim 132 , wherein the composition is in the form of a drop. 
     
     
         135 . The composition according to  claim 134 , wherein the volume of the drop is less than 35 ml. 
     
     
         136 . The composition according to  claim 134 , wherein the drop comprises 35 micrograms or less of the estrogen or an estrogen analog or other estrogen receptor modulator. 
     
     
         137 . The composition according to  claim 132 , wherein the kerato-conjunctivitis sicca is associated with post-menopause, premature ovarian failure, post-operative refractive surgery or a corneal transplant. 
     
     
         138 . The composition according to  claim 132 , wherein the estrogen or estrogen analog or other estrogen receptor modulator is 17-β-estradiol. 
     
     
         139 . The composition according to  claim 132 , wherein the thermosetting gel comprises polyethylene glycol. 
     
     
         140 . The composition according to  claim 132 , wherein the thermosetting gel comprises poloxamer. 
     
     
         141 . The composition according to  claim 132 , wherein the thermosetting gel comprises polyethylene glycol and poloxamer.